Combination therapy with Ezetimibe and Gemfibrozile on post-prandial hypertriglyceridemia

The effect of combination therapy with Ezetimibe and Gemfibrozile on post-prandial hypertriglyceridemia in type 2 Diabetic patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201105311179N5

Enrollment

Registered

2011-06-27

Start date

2011-01-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: Group1:ezetimibe 10mg plus gemfibrozile 1200mg. Intervention 2: Group 2:1200mg gemfibrozile. Intervention 3: Group3: ezetimibe 10mg plus atorvastatin 10mg.

Treatment - Drugs

Group1:ezetimibe 10mg plus gemfibrozile 1200mg

Group 2:1200mg gemfibrozile

Group3: ezetimibe 10mg plus atorvastatin 10mg

Eligibility

Sex/Gender

All

Age

20 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: The average age of 20-65-HbA1C 250mg/dl?Patients with DM type 2 Exclusion criteria: Treating with antilipid agents, thyroid disease, acute or chronic liver disease, association with other endocrine disease like Acromegaly or cushing , renal dysfunction (GFR1000 and LDL >190mg/dl

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Lipid profile. Timepoint: 6 weeks. Method of measurement: labratory.	—

Secondary

Measure	Time frame
Apo protein B. Timepoint: 6 weeks. Method of measurement: labratory.;Apo protein A. Timepoint: 6 weeks. Method of measurement: labratory.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Faranak Sharifi

Zanjan Metabolic Diseases Research Center

faranaksharifi@hotmail.com+98 24 1727 0815

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026